DUBLIN–(BUSINESS WIRE)–The “Neutropenia Biologic Drug Remedy International Market Report 2021: COVID-19 Progress and Change to 2030” report has been added to ResearchAndMarkets.com’s providing.

The worldwide neutropenia biologic drug remedy market is predicted to develop from $11.55 billion in 2020 to $12.19 billion in 2021 at a compound annual progress charge (CAGR) of 5.5%. The market is predicted to succeed in $14.45 billion in 2025 at a CAGR of 4%.

Main gamers within the neutropenia biologic drug remedy market are Teva Pharmaceutical, Amgen, Sanofi, Mylan, Kyowa Kirin, Baxter Worldwide, CVS Well being Corp, Novartis, Spectrum Prescribed drugs, and Accomplice Therapeutics.

The neutropenia biologic drug remedy market consists of gross sales of biologics used for the remedy of neutropenia and associated providers by entities (organizations, sole merchants and partnerships) that produce biologics for neutropenia remedy. Neutropenia is a scientific situation characterised by a lower in neutrophil depend within the blood, leading to the next threat of growing critical infections. A neutrophil is a sort of white blood cell, which helps in preventing infections.

The foremost causes of neutropenia embrace most cancers chemotherapy, infections, bone marrow problems, autoimmune problems, and using particular medication. The market consists of income generated by the corporate’s manufacturing the neutropenia biologic medication by the gross sales of those merchandise.

The neutropenia biologic drug remedy market coated on this report is segmented by drug sort into filgrastim, pegfilgrastim, lenograstim, lipegfilgrastim, sargramostim. It is usually segmented by remedy sort into antibiotic medication, granulocyte-colony-stimulating issue (G-CSF), antifungal medication, others and by distribution channel into retail pharmacies, hospital pharmacies, on-line pharmacies.

The introduction of biosimilars on account of patent expiry is predicted to hamper the expansion of the neutropenia biologic drug remedy market. Biosimilar is a therapeutic agent, which has excessive similarity with the unique organic product in motion however is accessible at a decrease value than the price of the unique product. Biosimilars are largely priced at 70% of the branded drug worth and are more likely to change costly branded medication. These cheaper options enhance competitors within the biologics market placing downward stress on pricing and market worth progress.

The rise within the variety of most cancers instances throughout the globe is more likely to contribute to the expansion of the neutropenia biologic medication market. Because of a rising most cancers incidence and a rise within the variety of individuals choosing chemotherapy, there was an rising incidence within the variety of individuals affected by neutropenia. Subsequently, the rise in most cancers incidence charge globally is anticipated to spice up the demand for the neutropenia biologic drug remedy market over the forthcoming years.

Corporations within the neutropenia biologic drug remedy market are more and more investing in growing novel drug supply programs to enhance the therapeutic response of the drug and enhance its efficacy. Novel drug supply programs permit the supply of a really excessive dose of medicine immediately into the neutrophils, whereas the systemic dose stays low, thus disallowing side-effects.

Key Subjects Coated:

1. Government Abstract

2. Neutropenia Biologic Drug Remedy Market Traits

3. Neutropenia Biologic Drug Remedy Market Developments and Methods

4. Influence Of COVID-19 On Neutropenia Biologic Drug Remedy

5. Neutropenia Biologic Drug Remedy Market Dimension and Progress

5.1. International Neutropenia Biologic Drug Remedy Historic Market, 2015-2020, $ Billion

5.1.1. Drivers Of the Market

5.1.2. Restraints On the Market

5.2. International Neutropenia Biologic Drug Remedy Forecast Market, 2020-2025F, 2030F, $ Billion

5.2.1. Drivers Of the Market

5.2.2. Restraints On the Market

6. Neutropenia Biologic Drug Remedy Market Segmentation

6.1. International Neutropenia Biologic Drug Remedy Market, Segmentation by Drug Kind, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

  • Filgrastim
  • Pegfilgrastim
  • Lenograstim
  • Lipegfilgrastim
  • Sargramostim

6.2. International Neutropenia Biologic Drug Remedy Market, Segmentation by Remedy Kind, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

  • Antibiotic Medicine
  • Granulocyte-Colony-Stimulating Issue (G-CSF)
  • Antifungal Medicine
  • Others

6.3. International Neutropenia Biologic Drug Remedy Market, Segmentation by Distribution Channel, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

  • Retail Pharmacies
  • Hospital Pharmacies
  • On-line Pharmacies

7. Neutropenia Biologic Drug Remedy Market Regional and Nation Evaluation

7.1. International Neutropenia Biologic Drug Remedy Market, Cut up by Area, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

7.2. International Neutropenia Biologic Drug Remedy Market, Cut up by Nation, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

Corporations Talked about

  • Teva Pharmaceutical
  • Amgen
  • Sanofi
  • Mylan
  • Kyowa Kirin
  • Baxter Worldwide
  • CVS Well being Corp
  • Novartis
  • Spectrum Prescribed drugs
  • Accomplice Therapeutics
  • Pfizer
  • Myelo Therapeutics
  • Cellerant Therapeutics
  • Sandoz (Subsidary of Novartis AG)
  • BeyondSpring Prescribed drugs
  • Enzychem Lifesciences Company
  • Tianjin SinoBiotech
  • S&D Pharma SK s.r.o.
  • Generon (Shanghai) Company Ltd.
  • PhytoHealth Company
  • Dong-A ST Co.

For extra details about this report go to https://www.researchandmarkets.com/r/kf3m3b

Contacts

ResearchAndMarkets.com

Laura Wooden, Senior Press Supervisor

press@researchandmarkets.com
For E.S.T Workplace Hours Name 1-917-300-0470

For U.S./CAN Toll Free Name 1-800-526-8630

For GMT Workplace Hours Name +353-1-416-8900

Copyright © acrofan/Enterprise Wire All Proper Reserved



Supply hyperlink

About Author

Leave a Reply

Leave a Reply

Your email address will not be published.

Translate »